Cern-Medicis (MEDical Isotope Collected from ISolde): A new facility [1]

by Thierry Stora (CERN)

Thursday 19 Feb 2015, 14:15 → 15:30 Europe/Zurich

30/7-018 - Kjell Johnsen Auditorium (CERN)

About 50% of the 1.4 GeV PSB protons are sent onto targets to produce radioactive beams by online mass separation [2] at the Isotope Separator Online Device (ISOLDE) facility, for a wide range of studies in fundamental and applied physics [3]. CERN-MEDICIS is a spin-off dedicated to R&D in life sciences and medical applications. It is located in an extension of the Class A building presently under construction. It will comprise laboratories to receive the irradiated targets from a new station located at the dump position behind the ISOLDE HRS production targets. An increasing range of innovative isotopes will thus progressively become accessible from the start-up of the facility onward, for fundamental studies in cancer research, for new imaging and therapy protocols in cell and animal models and for pre-clinical trials, possibly extended to specific early phase clinical studies up to Phase I trials [4]. Five hundred megabecquerel isotope batches purified by electromagnetic mass separation combined with chemical methods will be collected on a weekly basis. A possible future upgrade with gigabecquerel pharmaceutical-grade batch production capabilities is also presented.

---

[1] dos Santos Augusto R.M., Buehler L., Lawson Z., Marzari S., Stachura M., Stora T., CERN-MEDICIS (Medical Isotopes Collected from ISOLDE): A New Facility. Appl. Sci. 2014, 4, 265-281.

[2]  Sato T.K., Asai M., Borschevsky A., Stora T., Sato N., et al., Measurement of the first ionization potential of lawrencium (element 103), Nature, to be published (2015).

[3] Gaffney, L. P., Butler, P. A., Scheck, M., Hayes, A. B., Wenander, F., et al., Studies of pear-shaped nuclei using accelerated radioactive beams. Nature, 497(7448), 199-204 (2013).

[4]  Buchegger F., Viertl D., Kosinski M., Prior, J. O., Stora T., Bühler L.,  Müller C., Maecke H. R., Mansi R., Prostate cancer therapy with a GRP receptor antagonist radiopeptide compared&combined with fractionated external beam radiation therapy, to be submitted.

 

ATS Seminars Organisers: H. Burkhardt (BE), M. Modena (TE), T. Stora (EN)

Coffee / tea will be served after the seminar in room 30/7-012 (TE amphi coffee area)